iShares 7-10 Year Treasury Bond ETF vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.4 (market cap $41.13B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 6.8× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| IEF | IOVA | |
|---|---|---|
Market Cap | $41.13B | $6.04B |
Volume | 10,340,382 | 14,805,993 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $14.82 |
52-Week Low | $88.92 | $1.81 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | — | $5.97B |
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.45, up 0.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 52.94, while ADX indicates strong bearish momentum. Recent dividend payments of $0.31-$0.33 provide income support amid challenging bond market conditions. Key support sits at $89 with resistance at $90, creating a tight trading range.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current levels may offer entry points for income-focused investors, persistent inflation and Fed policy uncertainty pose significant risks. The bearish technical setup suggests continued pressure unless macroeconomic conditions improve.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →